IL1B and adult-onset Still disease: Increasing evidence regarding the efficacy of IL-1 inhibitors such as anakinra (IL-1 receptor antagonist) and canakinumab (monoclonal anti-IL-1β antibody) has been collected from patients with refractory AOSD [16, 17].